SCHEMBL10442385

SCHEMBL10442385

CNC(=O)C(CN)NC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20366275 0.81 GABRR1 (0.38)
SCHEMBL10442144 0.81 GABRR1 (0.38)
SCHEMBL14143227 0.79 TSHR (0.32)
SCHEMBL19681471 0.79 ADH1B (0.33)
SCHEMBL15679192 0.79 KDM4E (0.42)
SCHEMBL25556371 0.78 MMP1 (0.40)
SCHEMBL19849408 0.77
SCHEMBL12914613 0.77
SCHEMBL22449492 0.77
SCHEMBL8288935 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222215-B2 Methods for the use of inhibitors of antigen presentation by MHC class II molecules PROVID PHARMACEUTICALS, INC. (US) 2012-07-17 US disclosed
US-20090253166-A1 Conjugation of Peptides NOVO NORDISK A/S (DK) 2009-10-08 US disclosed
US-20090111755-A1 METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES PROVID PHARMACEUTICALS, INC. 2009-04-30 US disclosed
US-7524813-B2 Selectively conjugated peptides and methods of making the same NOVO NORDISK HEALTH CARE AG (CH) 2009-04-28 US disclosed
US-20090105134-A1 C-Terminally Pegylated Growth Hormones NOVO NORDISK A/S (DK) 2009-04-23 US disclosed
US-7439231-B2 Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof PROVID PHARMACEUTICALS, INC. (US) 2008-10-21 US disclosed
US-20070111926-A1 Conjugation of peptides NOVO NORDISK A/S (DK) 2007-05-17 US disclosed